US4252902A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for purification of crude kallikrein
Assignee: Toho Pharmaceutical Industries Co Ltd
•
Filing: 1979-07-17
•
Granted: 1981-02-24
•
Expires: 1999-07-17
Abstract
Abstract A process for purification of crude kallikrein utilizing a specific affinity of kallikrein to p-aminobenzamidine, which comprises bringing a solution, containing kallikrein and contaminated by other undesirable enzymes and proteins, into contact with a water-insoluble carrier combined with p-aminobenzamidine, exclusively eluting out the other enzymes and proteins from the carrier by the use of a buffer solution of lower NaCl concentration and then exclusively eluting out kallikrein by the use of a buffer solution of higher NaCl concentration.
Inventors
- 👤 Setsuro Fujii
- 👤 Kiyoaki Noda
- 👤 Akio Yokoshima
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 11:26
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6445; Y; Y10; Y10S; Y10S435/00; Y10S435/814; Y10S435/815
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
91 words
A process for purifying crude mammal-pancreas-derived kallikrein containing undesirable enzymes or proteins which comprises: (a) bringing a solution containing the kallikrein, other enzymes and proteins into contact with water-insoluble carrier, (b) eluting out the other enzymes and proteins from the carrier with buffer solution having a low NaCl concentration from 0.05 to 0.2 M and a pH below 7.4 and then (c) eluting out kallikrein from the carrier with buffer solution having a higher NaCl concentration and a pH below 7.4, the water-insoluble carrier being one which is combined with p-aminobenzamidine.
Claim 2
Dependent Claim
91 words
A process for purifying crude mammal-pancreas-derived kallikrein containing undesirable enzymes or proteins which comprises: (a) bringing a solution containing the kallikrein, other enzymes and proteins into contact with water-insoluble carrier, (b) eluting out the other enzymes and proteins from the carrier with buffer solution having a low NaCl concentration from 0.05 to 0.2 M and a pH below 7.4 and then (c) eluting out kallikrein from the carrier with buffer solution having a higher NaCl concentration and a pH below 7.4, the water-insoluble carrier being one which is combined with p-aminobenzamidine.
Claim 3
Dependent Claim
27 words
A process according to claim 1, wherein the carrier is combined with p-aminobenzamidine via a spacer capable of being bound to both of the carrier and p-amino-benzamidine.
Claim 4
Dependent Claim
12 words
A process according to claim 2, wherein the spacer is ε-aminocaproic acid
Claim 5
Dependent Claim
20 words
A process according to any one of claims 2 and 3, wherein the carrier is agarose activated by cyanogen bromide.
Claim 6
Dependent Claim
21 words
A process according to claim 1, wherein the buffer solution is a phosphate buffer having a pH between 6.9 and 7.4.
Claim 7
Dependent Claim
17 words
A process according to claim 1 wherein the higher NaCl concentration is from 0.5 to 2.0 M.
Claim 8
Dependent Claim
15 words
A process according to claim 1 wherein the p-aminobenzamidine is chemically bound to the carrier.
References Cited (Backward Citations)
US3100736A
Cited
US3746622A
Cited
US4020268A
Cited
US3912595A
Cited
JPS5218883A
Cited
US3994782A
Cited
US4064010A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-02-24 | 1984-08-25 | 1985-02-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-02-24 | 1988-08-25 | 1989-02-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-02-24 | 1992-08-25 | 1993-02-24 | $7700.00 | Window Closed / Lapsed |